Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.